Full-Time

Lead – QMS & Training

Confirmed live in the last 24 hours

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

201-500 employees

Develops treatments for neurodegenerative diseases

Biotechnology
Healthcare

Senior

Remote in USA

Must reside and work within the United States in a state where Amylyx currently does business.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • B.S. in Pharmaceutical Sciences, Biotechnology or equivalent (advanced degree a plus).
  • Minimum 5 years of experience within the Pharmaceutical or Biotechnology industry in a quality role.
  • Working knowledge of QMS electronic platforms e.g. Veeva, Pilgrim, TrackWise, ZenQMS, etc. (Experience with Veeva a plus)
  • Ability to partner with all levels of the organization and external contract service providers to ensure compliance with current regulations.
  • Experience in developing and implementing GxP quality and Training systems to meet regulatory and industry standards.
  • Knowledgeable in FDA cGMP regulations, Eudralex and ICH Guidance, as well as other Biopharma industry guidance and regulations.
  • Experience in supporting functions during FDA, EMA or other regulatory agency inspections.
  • Travel may be required up to 10%, which may include on-site review of third-party operations.
Responsibilities
  • Responsible for overseeing activities related to Training and Personnel Qualification, including creation and maintaining curricula and associated documentation, to ensure individuals meet GxP compliance and regulatory requirements.
  • Own implementation, validation, and management for training systems, including software validation and User Acceptance Testing (UAT), through working closely with IT.
  • Monitor the overall health of Training compliance, generate meaningful KPIs and drive continuous improvement of the training system.
  • Coordinate workflows for GxP documentation and training updates; at times will/may include Deviations, OOS, investigations, etc. that occur during production and testing, supporting proper creation of CAPA and other applicable remediation plans.
  • Partner with departments to facilitate their writing, review and/or approval of their SOPs for clinical and commercial systems to ensure they are integrated into the training system/process.
  • Provide system oversight, ensure system compliance and usage to regulatory and corporate requirements as they relate to training, document control and lifecycle records management.
  • Support implementation and qualification of software for all Quality Management Systems as needed.
  • Support quality improvements to maintain compliance and improve efficiency as part of continuous improvement initiatives.
  • Participate in inspection readiness across the GxP departments.
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials, including the CENTAUR ALS trial, which showed significant benefits for ALS patients through a randomized, double-blind, placebo-controlled study. They are also conducting the PEGASUS trial to assess AMX0035's safety and effectiveness for Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.

Company Stage

IPO

Total Funding

$166.7M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

-38%

1 year growth

-33%

2 year growth

1%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful acquisition of Phase 3-ready avexitide from Eiger could diversify Amylyx's pipeline and open new revenue streams.
  • Interim data from the Phase 2 HELIOS trial shows promising results for AMX0035 in treating Wolfram syndrome, indicating potential for broader applications.
  • The appointment of experienced professionals like Dr. Bernhardt Zeiher to the Board of Directors strengthens the company's leadership and strategic direction.

What critics are saying

  • The failure of the Phase III PHOENIX trial and subsequent market withdrawal of Relyvrio raises concerns about the efficacy of Amylyx's treatments.
  • A significant workforce reduction by 70% under a restructuring plan could impact company morale and operational efficiency.

What makes Amylyx Pharmaceuticals unique

  • Amylyx Pharmaceuticals focuses on neurodegenerative diseases like ALS and Alzheimer's, setting it apart from competitors with broader therapeutic areas.
  • The company's flagship product, AMX0035, has shown significant treatment benefits in rigorous clinical trials, including the CENTAUR ALS trial, which is a strong validation of its efficacy.
  • Amylyx's commitment to community engagement and awareness campaigns, such as ALS Awareness Month, enhances its brand and builds a supportive community around its cause.

Help us improve and share your feedback! Did you find this helpful?